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Summary
 
Intradermal administration of short overlapping peptides derived from chain 1 of the cat aller-
gen Fel d 1 (FC1P) that did not cross-link IgE, elicited isolated late asthmatic reactions with no
visible early or late cutaneous response in 9/40 cat-allergic asthmatics. Four of the nine were
human histocompatibility leukocyte antigen DR13–positive, as compared with only 1/31 non-
reactors. The other five reactors expressed either DR1 or DR4. To confirm major histocom-
patibility complex restriction, fibroblast cell lines transfected with HLA-DR molecules were
used to present FC1Ps to cat allergen–specific T cell lines derived from subjects before peptide in-
jection. FC1P3 (peptide 28–44 of Fel d 1 chain 1) was recognized in the context of DR13 alleles
 
(DRB1
 
*
 
1301, 1302) and induced specific T cell proliferation and IL-5 production. T cells from a
DR1
 
1
 
 responder proliferated and produced IL-5 in the presence of FC1P3 and DR1
(DRB1
 
*
 
0101) fibroblast cell lines, whereas T cells from a DR4
 
1
 
 subject recognized FC1P2 (pep-
tide 22–37) when presented by DRB1
 
*
 
0405. We conclude that short, allergen-derived peptides
can directly initiate a major histocompatibility complex–restricted, T cell–dependent late asth-
matic reaction, without the requirement for an early IgE/mast cell–dependent response, in sensi-
tized asthmatic subjects.
Key words: T lymphocyte • Fel d 1 • allergen • allergy • human histocompatibility leukocyte 
antigen
 
A
 
llergen challenge of sensitized atopic individuals results
in an early response, which in the skin is seen as the
immediate wheal and flare reaction, and, after inhalation, as
a decrease in airway caliber occurring within minutes (1).
These acute reactions are generally considered to be due to
the release of histamine and other pharmacological agents
from mast cells subsequent to IgE cross-linking. 3–8 h after
 
allergen challenge, there follows a late-phase reaction (LPR)
 
1
 
characterized in the skin by swelling and induration (1) and
in the lung by the late asthmatic reaction (LAR). LPRs are
accompanied by inflammatory cell infiltration, in particular
eosinophils and Th2 cells (2, 3), and have been used as
models of chronic allergic inflammation. There is contin-
ued debate as to the relative contributions of IgE-depen-
dent versus T cell–dependent mechanisms in the pathogen-
esis of the LPR. On the one hand, a cutaneous LPR could
be transferred by IgE or injection of anti-IgE (4, 5),
whereas we and others have provided extensive evidence
that CD4
 
1
 
 T cells are associated with the LPR and chronic
asthma (3, 6–8). Furthermore, in animal models, airway eosin-
ophil responses and bronchial hyperresponsiveness to in-
haled antigen challenge could be adoptively transferred by
CD4
 
1
 
 T cells alone (9, 10).
To provide evidence that the LPR can be provoked by T
cell activation independently of the early IgE response, we
have administered peptide epitopes derived from the major
cat allergen, Fel d 1, to cat-allergic asthmatics. The peptides
were capable of inducing T cell proliferation but did not
cross-link IgE, as shown by the basophil histamine release as-
say. We hypothesized that the peptides would elicit isolated
late cutaneous reactions after intradermal injection, without a
preceding wheal and flare reaction. Unexpectedly, we ob-
served that intradermal injection of the T cell peptide
epitopes produced isolated LARs with no visible cutaneous
response. These reactions were only observed in a minority
of the subjects challenged. In this report, we describe these
isolated LARs provoked by T cell peptide epitopes and pro-
vide evidence that they are HLA restricted. We also present
preliminary observations on hyporesponsiveness (“tolerance”)
after subsequent rechallenge with the peptides.
 
1
 
Abbreviations used in this paper:
 
 AUC, area under curve; BAL, bronchoal-
veolar lavage; FEV
 
1
 
, forced volume in 1 s; LAR, late asthmatic reaction;
LPR, late-phase reaction; PPD, purified protein derivative. 
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Materials and Methods
 
Human Subjects.
 
40 cat-allergic asthmatic patients were re-
cruited from the Allergy Clinic, Royal Brompton Hospital, Lon-
don and by advertisement. The study was approved by the Royal
Brompton Hospital Ethics Committee, and informed consent
was obtained from all patients. Subjects were nonsmokers and
had no other significant illness. Inhaled corticosteroids were dis-
continued at least 2 d before assessment, and oral corticosteroids
were discontinued 3 mo before assessment. Patients were specifi-
cally instructed not to take antihistamines, corticosteroids, or any
other medication for the duration of the study. Volunteers had a
history of wheezing on exposure to cats and demonstrated airway
hyperresponsiveness, with a provocative concentration (PC)
 
20
 
 of
 
,
 
4 mg/ml methacholine, and 
 
.
 
20% reversibility with inhaled 
 
b
 
2
 
agonists. Cat allergy was confirmed by a positive radio allergo
sorbent test (
 
.
 
0.35 IU/ml; Pharmacia) and skin prick test to
whole cat dander (ALK) and a late phase skin reaction of 
 
.
 
3 cm
diameter at 6 h, after the intradermal testing of 30 biological units
of whole cat dander (containing 4.5 ng Fel d 1) in 0.03 ml. The ve-
hicle for whole cat dander extract contained 0.3 mg/ml human
serum albumin and 4 mg/ml phenol (ALK diluent; ALK).
 
Study Design.
 
On the first visit (control day), subjects were
skin tested with intradermal cat dander. Peripheral blood (150 ml)
was taken for HLA typing, histamine release assays, and prolifera-
tion assays. Local reactions were observed after 5, 15, and 30 min
and hourly for 6 h thereafter. At these times, FEV
 
1
 
 and peak expi-
ratory flow rate were also recorded. On the second visit, patients
received 40 
 
m
 
g intradermally of the three peptides comprising
FC1P, contained in 25 
 
m
 
l, into each forearm. Local reactions were
observed at the same time points as the control day. A positive re-
action was defined as a fall in forced volume in 1 s (FEV
 
1
 
) of 20% or
more. The time interval between the two study days ranged from
4 to 56 d (average, 17 d). Six of the nine subjects who developed
LARs after peptide injections had a further visit in which 0.03 ml
of diluent (vehicle) was injected intradermally. Three subjects, hav-
ing developed LAR after FC1P administration, were recalled for a
repeat administration of the peptides 2–6 wk after the initial chal-
lenge. An additional three subjects received a repeat administration
of FC1P a minimum of 12 mo after the first injection.
 
Statistical Analysis of LARs.
 
FEV
 
1
 
 data was summarized over
time for each subject for the control and peptide days. Areas under
each curve were calculated using the trapezoidal rule to generate
area under curve (AUC). Differences in the AUC between the
control day and the peptide day were analyzed by paired 
 
t
 
 test.
 
Peptide Synthesis.
 
The three FC1Ps for injection were synthe-
sized by F-moc chemistry and supplied as acetate salts. They were
purified to 
 
.
 
95% by HPLC, subjected to sequence and mass anal-
ysis, and subjected to independent analysis for sterility and the ab-
sence of endotoxin. Peptides were reconstituted in ALK diluent at
1.6 mg/ml. Peptides for in vitro analysis were synthesized using
F-moc chemistry at the Advanced Biotechnology Centre, Imperial
College School of Medicine, Charing Cross Campus. Peptide se-
quences used in this study were: FC1P1, LFLTGTPDEYVEQ-
VAQY; FC1P2, EQVAQYKALPVVLENA; and FC1P3, KALP-
VVLENARILKNCV. Cat allergen extract was a gift of ALK
Abello, Copenhagen, Denmark.
 
Histamine Release Assays.
 
In 11 subjects, PBMCs isolated by
density centrifugation from 50 ml of blood were washed three
times with Ca
 
2
 
1
 
- and Mg
 
2
 
1
 
-free HBSS. 100-
 
m
 
l aliquots of cell
suspension at 5 
 
3
 
 10
 
6
 
 cells/ml were combined with an equal vol-
ume of peptide (0.02–100 
 
m
 
g/ml) or cat dander (0.02–200 
 
m
 
g/ml).
Samples were incubated at 37
 
8
 
C for 60 min, followed by centri-
fugation. Supernatants were transferred to glass microfiber–coated
 
microtiter plate wells (REFLAB), together with 50 
 
m
 
l of a hista-
mine standard solution (50 ng/ml). Plates were incubated at 37
 
8
 
C for
60 min, washed twice (45 s) in distilled water, and air dried before
measurement of histamine by spectrofluorimetry. Percentage of
histamine release for each control and test substance was calculated
from the mean histamine release (ng/ml) values using the equation:
% release
 
 5 
 
[(sample 
 
2
 
 spontaneous)/(total 
 
2
 
 spontaneous)] 
 
3
 
 100.
 
Transfected Fibroblast Cell Lines.
 
Murine and human fibro-
blast cell lines transfected with HLA-DR molecules were obtained
as gifts from a number of sources: DRB1
 
*
 
0101, 0401, 0403, 0404,
and 0406 from Prof. R.I. Lechler and Dr. G. Lombardi (Imperial
College School of Medicine [ICSM], Hammersmith Campus,
London), DRB1
 
*
 
0402 and 0405 from Prof. J.R. Lamb (Univer-
sity of Edinburgh, UK) and Dr. A. Verhoef (ICSM at National
Heart and Lung Institute [NHLI], London), and DRB1
 
*
 
1301,
1302, 1303, 1304, and 1305 from Drs. J.R. Richert and C. Kato-
vich Hurley (Georgetown University Medical Center, Washing-
ton, DC). Cells were cultured in RPMI 1640 supplemented with
10% fetal bovine serum, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin,
100 
 
m
 
g/ml streptomycin, and 250 
 
m
 
g/ml G418 (all from GIBCO
BRL).
 
Allergen-specific T Lymphocyte Lines.
 
PBMCs were isolated by
density gradient centrifugation from all subjects at the initial screen-
ing visit. PBMCs were either frozen for subsequent use as APCs or
cultured for 10 d in the presence of cat allergen extract (100 
 
m
 
g/ml;
ALK) with addition of purified human IL-2 (Lymphocult LF;
Biotest) at a final concentration of 10% on day 6 of culture. Viable
cells were harvested and restimulated weekly with cat allergen
extract and IL-2, with a further addition of IL-2 on day 3 of the
restimulation cycle. Before assay, cells were rested overnight in
culture medium in the absence of exogenous antigen or IL-2.
 
Primary PBMC Proliferation Assays.
 
PBMCs were separated from
100 ml whole blood in 25 patients by density centrifugation.
PBMCs were washed and resuspended in RPMI supplemented with
5% vol/vol AB-serum (Sigma Chemical Co.), 2 mM 
 
l
 
-glutamine,
100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin and cultured at
10
 
5
 
 cells/well in 96-well plates. 16 replicate wells for each of three
concentrations were established for each peptide. Purified protein
derivative (PPD; 10 
 
m
 
g/ml) was used as positive control. Cells were
cultured for 6 d before addition of 1 
 
m
 
Ci (37 kBq) tritiated methyl-
thymidine per well for 8 h. Cells were harvested, and thymidine in-
corporation was determined by liquid scintillation spectroscopy. In-
dividual data points for 16 peptide culture wells were compared with
those containing medium alone. Statistical evaluation was performed
using Mann-Whitney analysis. Results are expressed as delta counts
per minute (observed cpm 
 
2
 
 medium-alone cpm).
 
T Cell Line Proliferation Assays in the Presence of Transfected Fibro-
blast Lines.
 
Transfected fibroblast lines were cultured overnight
in the presence of the relevant peptide at a concentration of 100
 
m
 
g/ml before harvesting and incubation with mitomycin C (50
 
m
 
g/ml) for 1 h. Cells were washed extensively before seeding in
96-well, flat-bottomed plates at 3 
 
3
 
 10
 
4
 
 cells/well. Allergen-speci-
fic T lymphocytes were added (10
 
4
 
 cells/well) and cultured for 48 h.
Culture supernatants were harvested for cytokine analysis before
pulsing wells with 37 kBq/well of tritiated methyl-thymidine and
cultured for a further 8 h. Proliferation as correlated with thymi-
dine incorporation was measured by scintillation spectroscopy
(TopCount; Canberra Packard).
 
ELISA for Cytokines.
 
IL-5 was measured in the laboratory of
Dr. D. Huston (Baylor Medical Center, Houston, TX) according
to a previously described technique (11). The sensitivity of the
assay was 3 pg/ml. 
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Results
 
Incubation of FC1P with Basophil-enriched PBMCs Did Not
Induce Histamine Release.
 
In contrast to whole cat extract
(ALK cat), pooled FC1Ps did not release histamine from
basophil-enriched mononuclear cells in vitro. Cells from
11 subjects (5 FC1P reactors and 6 nonreactors) were incu-
bated with FC1Ps at five increasing concentrations up to
100 
 
m
 
g/ml (
 
z
 
5 
 
3
 
 10
 
2
 
5
 
 M of each of the pooled peptides).
Whole cat dander extract served as a positive control, re-
leasing histamine in all subjects assayed (Fig. 1). No imme-
diate skin or asthmatic reactions were observed in vivo,
further demonstrating that FC1P did not bind IgE.
 
FC1Ps Induce Primary Proliferative Responses in PBMC
Culture.
 
The ability of FC1Ps to stimulate T cell re-
sponses was assessed, initially by primary in vitro prolifera-
tion assays. All individuals assayed responded to one or
more of the three peptides, although none of the peptides
induced proliferation in all individuals, suggesting MHC-
restricted recognition. Each of the peptides was recognized
by PBMCs from both the group developing LARs (
 
n
 
 5 
 
7)
and the nonresponder group (
 
n
 
 5 
 
19). As shown in Fig. 2,
each peptide was able to induce proliferative responses, in a
dose-dependent fashion, in PBMCs from representative
(26/40) cat-asthmatic subjects from whom cells were avail-
able. Proliferative responses from individuals who devel-
oped LARs were generally of greater magnitude than those
that did not; however, this difference was not statistically
significant. All subjects responded to the positive control
recall antigen, PPD.
 
Intradermal Administration of Peptides Derived from Fel d 1
Induced Isolated LARs.
 
Inhaled whole allergen induces
both an immediate early asthmatic reaction and an LAR.
To determine whether T cell activation could trigger an
isolated LAR, sensitized volunteers were challenged with
peptides derived from Fel d 1 chain 1. In 9/40 subjects, 80
 
m
 
g of FC1P did not produce a visible immediate or late
skin reaction but did elicit a progressive decline in FEV
 
1
 
,
associated, in all responders, with symptoms of chest tight-
ness and wheezing. The remaining subjects did not develop
any immediate or late bronchial or cutaneous reactions to
the peptides. The reaction commenced at hours 2–3 and
reached a plateau by hour 6 (Fig. 3). The decrease in FEV
 
1
 
observed ranged from 21 to 64% of baseline. AUC analysis
to compare percentage change in FEV
 
1 
 
on control and
FC1P days in nine patients was statistically significant, at
 
 P 
 
5
 
0.0004. Subjects were monitored for a minimum of 6 h
and treated with 
 
b
 
2
 
 agonists and inhaled corticosteroids be-
fore leaving the hospital. The mean maximum change in
FEV
 
1
 
 observed on the whole cat dander control day was
 
2
 
3.83% (range 
 
2
 
14 to 
 
1
 
4%). Additionally, six of the nine
reactors had a further control day in which 0.03 ml of the
diluent (vehicle) was injected intradermally. The mean
Figure 1. FC1Ps do not induce histamine release from basophil-
enriched PBMC in vitro. Mean percentage histamine release induced by
whole cat dander extract (ALK; 0.2, 2, 20, 100, and 200 mg/ml) and
FC1P (five increasing concentrations up to 100 mg/ml [5 3 1025 M])
from basophil-enriched leukocytes (n 5 11; five LAR responders and six
nonresponders).
Figure 2. Proliferation occurs in primary PBMC cultures from reactors and nonreactors in response to peptides FC1P 1, FC1P 2, and FC1P 3. T cell
reactivity to FC1P in (A) subjects developing LARs and (B) nonreactors. Delta counts per minute (Dcpm) from PBMC proliferating to peptides FC1P 1,
2, and 3 at up to three concentrations. All patients reacted to tuberculin (PPD; positive control) with a mean Dcpm of 65,112 (data not shown). Back-
ground counts ranged from 680 to 4,465 cpm. d, statistically significant proliferative responses (see Materials and Methods) compared with background;
s, nonstatistically significant proliferative responses. Each peptide was capable of eliciting a proliferative response, in a dose-dependent fashion, in indi-
viduals from both groups (responders, n 5 7; nonresponders, n 5 19); however, none of the peptides induced proliferation in all individuals. 
1888
 
T Cell Peptide Epitope–induced Late Asthmatic Reactions
 
maximum change in FEV
 
1
 
 was 
 
2
 
6.3% (range from 0 to
–13%). 31 individuals showed no evidence of LAR (Fig. 3).
 
Subjects Who Developed an LAR Demonstrated a Higher
Frequency of HLA-DR13 than Nonreactors.
 
To determine
whether the reactions were HLA restricted, subjects were
typed for HLA-DRB1. HLA analysis revealed an increased
frequency of HLA-DR13 in those who developed LAR
(4/9 subjects), compared with only 1/31 subjects who did
not react, suggesting that DR13 may restrict T cell re-
sponses to one or more of the injected peptides (
 
P
 
 5 
 
0.006,
Fisher’s exact test). Patient characteristics and HLA-DRB1
types are shown in Table I.
 
Recognition of Peptides FC1P2 and 3 in the Context of DR13,
DR1, and DR4.
 
As peptides can be presented in vitro
without intracellular processing, we determined whether
Fel d 1 chain 1 peptides could be recognized in the context
of MHC molecules expressed by the subjects developing
asthmatic reactions. For this purpose, fibroblast cell lines
transfected with relevant HLA molecules were cultured to-
gether with each peptide and T cell lines from the respond-
ing individuals. Cat dander extract–specific T cell lines
were derived from a DR13
 
1
 
 subject (RO3; DRB1
 
*
 
1301)
before induction of peptide-induced LAR. Culture of
these cells with FC1Ps and a fibroblast cell line transfected
with DRA and DRB1
 
*
 
1301 resulted in T cell proliferation
and IL-5 secretion in response to FC1P3 but not to FC1P1
or FC1P2 (Fig. 4 A). Fibroblasts transfected with DRA and
DRB1
 
*
 
0101 were able to present FC1P3 to a cat dander
extract–specific T cell line derived from subject RO2
(DRB1
 
*
 
0101), resulting in proliferation and IL-5 produc-
tion (Fig. 4 B). T cells from a cat dander extract–specific
cell line from subject RO7 (DRB1*0405) were induced to
proliferate and release IL-5 when cultured with FC1P2
and fibroblasts expressing DRB1*0405 (Fig. 4 C).
Degenerate T Cell Recognition of FC1P3 on Closely Related
DR13 and DR4 Microvariants.  Fibroblast cell lines trans-
fected with either DRB1*1301 or DRB1*1302 were assayed
for their ability to present FC1P3 to allergen extract–specific
T cells derived from a DRB1*1301 donor. As previously de-
scribed, FC1P3 presented by DRB1*1301 induced a prolif-
erative response in autologous T cells (Fig. 4 A). In addition,
fibroblasts expressing DRB1*1302 were able to activate
allergen-specific T cells from a DRB1*1301 donor (Fig.
5 A). In the absence of fibroblasts expressing DRB1*0408,
cells expressing the closely related microvariant DRB1*0405
were assayed for their ability to present FC1P2 to cat allergen
extract–specific T cells from a DRB1*0408 donor. As shown
in Fig. 5 B, DRB1*0405, which differs from DRB1*0408 by
only one residue in the peptide binding groove (position 57,
serine®aspartic acid), was able to present FC1P2, inducing
proliferation in T cells from a DRB1*0408 donor.
Repeat Administration of Peptides Leads to Transient Attenu-
ation of the Initial Reaction. To study the reproducibility
of peptide-induced LAR, three subjects (RO1, RO4, and
RO5) received a second intradermal dose of 80 mg of
FC1P between 2 and 6 wk after the first injection. A
marked attenuation of the initial LAR was observed. The
maximum percentage changes in FEV1 on the first peptide
versus the second peptide challenge were 228 vs. 29
(R01), 221 vs. 210 (R04), and 251 vs. 29 (R05), respec-
tively (Fig. 6). After an interval of at least 12 mo after the ini-
tial FC1P challenge, three subjects received a further chal-
lenge of the same dose. All experienced LARs of similar
magnitude to those after the initial injection (Fig. 6 B).
Discussion
In this study, we have demonstrated that peptides derived
from a major allergen elicited an LAR in a proportion of
sensitized individuals. That the peptides were most likely to
initiate these reactions by direct activation of T cells, rather
than mast cells or basophils, is supported by (a) the lack of
IgE-mediated histamine release in vitro, (b) the absence of
a wheal and flare reaction at the site of injection, and (c) the
absence of an early asthmatic reaction. In addition, we have
demonstrated HLA restriction of T cell responses to pep-
tides FC1P2 and FC1P3 on the basis of fibroblast presenta-
tion assays. These observations provide direct evidence for
the central role of T lymphocytes in the induction of the
late asthmatic response and indicate that these reactions are
MHC-restricted events. Although we had a control day for
six of the nine responders that included the injection of
human serum albumin, we did not specifically employ a
control peptide. Some small peptides cause histamine re-
lease from mast cells, but because the action of histamine is
immediate, this would not be relevant to the LAR, which
commences at hour 2–3 and continues to hour 6. A pep-
tide of “irrelevant” sequence would not be informative, as
the biological actions are sequence dependent. On the other
hand, as we demonstrate MHC restriction of T cell recog-
Figure 3. Induction of isolated
LARs by intradermal injection of
peptides derived from FC1P. The
mean percent changes in FEV1 af-
ter intradermal administration of
FC1P (d) and during a control
day (s) of 9 responders (left) and
31 nonresponders (right). AUC
analysis to compare percent
change in FEV1 on control and
FC1P days in nine patients was
statistically significant, at P 5
0.0004. Error bars, SD.1889 Haselden et al.
Table I. Clinical Characteristics of Patients Injected with FC1P
Sex Age PC20 SPT Cat RAST Cat DRB1
mg/ml mm IU/ml
Responders
1 F 26 0.8 9 5.77 1, 7
2 F 22 1.5 10 6.25 1, 1302
3 F 41 2 11 42.8 7, 1301
4 F 28 2.5 8 0.54 17, 13
5 M 48 1.6 7 100 15, 1303
6 M 27 2.7 9 100 0408, 0801-11
7 F 46 2 5 34 0301, 0405
8F 3 0 ,2 6 12.1 0401, 0701
9 F 36 0.95 6 9.66 0101-2, 0104, 1101-16, 18-22
Nonresponders
1 F 29 3 8 1.7 01501-5, 0401
2M 2 2 ,4 5 1 0101-2, 0104, 0701
3 M 23 2 10 3.09 1301-1322
4 M 33 0.3 6 0.62 0301, 1201-3
5 M 22 2 10 1.13 ND
6 F 24 3.85 8 7.37 17, 4
7M 1 9 ,2 7 3.88 1501-5, 0405
8 M 35 3.22 9 3.21 1501-5, 0701
9 M 25 4 12 3.02 1701, 0301
10 F 24 2 7 1.39 0301/0304, 0408
11 F 37 2 6 4.65 0401-22, 0801-11
12 F 22 ,2 6 2.54 1501-5, 0301
13 F 25 3 5 2.03 0301, 0701
14 F 31 1.6 5 1.35 7, 11
15 F 31 3.5 8 4.99 16, 11
16 M 38 3 9 7.54 4, 7
17 M 25 2 7 3.68 0403, 0701
18 M 27 3.8 9 2.38 ND
19 F 23 3 9 6.94 1, 11
20 F 52 1.6 8 32.3 3(17), 4
21 F 38 2 12 3.91 4, 17
22 M 41 1.4 11 13.8 4, 11
23 F 34 1.7 9 3.04 1401, 08
24 F 25 3.6 6 1.29 0103, 7
25 M 23 3 8 60.4 0101, 0102, 0104, 1101-21
26 F 29 2 7 .100 ND
27 F 24 1.3 13 1.38 11, 0311, 0306, 03011-12
28 F 30 2.88 8 5.76 11, 04
29 M 25 1 14 9.44 0403, 1101-1121
30 F 29 1 13 .100 ND
31 F 23 3.6 8 2.54 04, 0701, 0703
RAST, radio allergo sorbent test; SPT, skin prick test.1890 T Cell Peptide Epitope–induced Late Asthmatic Reactions
nition, control peptide(s) would need to be immunologically
inactive but capable of binding to the same range of MHC
molecules as the FC1Ps and with similar affinities.
There is strong circumstantial evidence to support a role
for T lymphocytes in the pathogenesis of asthma (12). This
includes elevated numbers of activated T cells in the blood
of patients with acute severe asthma (8), as well as studies
using bronchoalveolar lavage (BAL) and bronchial biopsies
from mild asthmatics in which increases in CD3/CD41
cells expressing mRNA positive for IL-4 and IL-5 cells
were demonstrated (3, 7, 13). In a provoked model of
asthma, increased numbers of CD41 cells in BAL after al-
lergen challenge were also observed (14). Furthermore, the
allergen-induced late-phase, but not the early-phase, reac-
tion was inhibited by prior administration of cyclosporin A,
a compound with major inhibitory effects on CD41 cells
(15). More recently, a single infusion of humanized anti-
CD4 mAbs into patients with chronic asthma was associ-
ated with significant improvements in lung function (16).
In Brown Norway rats, Watanabe et al. showed increases
in airway resistance up to 8 h after adoptive transfer of CD4
but not CD8 T cells and subsequent allergen challenge (9).
Adoptive transfer experiments in mice have also demon-
strated that baseline airway hyperresponsiveness was T cell
dependent (10).
In animal models, initial administration of peptides in
sensitized mice can induce activation of primed T cells
(17). However, subsequent administration leads to the in-
duction of tolerance, not only to the peptide but to the
whole allergen (18). Using cat-sensitive asthmatics, Nor-
man et al. (19) attempted to induce the counterpart of mu-
rine experimental T cell tolerance in human atopic allergic
individuals by subcutaneous injection of two peptides
(termed IPC1 and IPC2) spanning a large proportion of
chain 1 of Fel d 1. Although there was some subjective
symptomatic improvement, many patients reported “aller-
gic” symptoms that occurred between 10 min and 6 h after
subcutaneous injections. Other groups, using the same
peptides, reported similar results (20, 21). As IPC1 and
IPC2 are 27 residues long (22), it is possible that the imme-
diate reactions were the result of IgE binding, and the late
reactions were due to T cell activation. For this reason, in
this study, we specifically designed peptides of relatively
small size (16/17 residues) and linear configuration to en-
able them to be presented to T cells in the absence of anti-
gen processing and without binding to IgE.
This approach, using T cell–reactive peptide epitopes
that do not cross-link IgE, provides evidence that asthma
can be provoked without initial mast cell activation. The
mechanism of T cell peptide–induced LPRs, however, re-
mains to be elucidated. One explanation is that T cell acti-
vation in the airways leads to mobilization of eosinophils
through the elaboration of type 2 and eosinophil active cy-
tokines (i.e., IL-3, IL-4, IL-5, and GM-CSF). Together,
these are known to promote selective eosinophil accumu-
lation, migration, activation, and subsequent tissue injury,
Figure 4. Restriction of T cell responses to FC1P 2 and 3 in the con-
text of DRB1*0405, DRB1*1301, and DRB1*0101. (A) Proliferation
and IL-5 production by a cat allergen extract–specific T cell line from
subject R03 (DRB1*1301) cultured with a fibroblast cell line transfected
with DRB1*1301 in the presence of medium alone and peptides FC1P 1,
2, and 3. Presentation of FC1P 3 by DRB1*1301 results in proliferation
and IL-5 production. (B) IL-5 production by a cat allergen extract–
specific T cell line from subject R02 (DRB1*0101, 1302) cultured with a
fibroblast cell line transfected with DRB1*0101 in the presence of
medium alone and peptides FC1P 1, 2, and 3. Presentation of FC1P 3 by
DRB1*0101 results in proliferation and IL-5 production. Responses in
the context of DRB1*1302 were not detected in this subject (data not
shown). (C) Proliferation and IL-5 production by a cat allergen extract–
specific T cell line from subject R07 (DRB1*0405) cultured with a
fibroblast cell line transfected with DRB1*0405 in the presence of
medium alone and peptides FC1P 1, 2, and 3. FC1P 2 is presented by
DRB1*0405, inducing proliferation and IL-5 production.1891 Haselden et al.
possibly through the generation of membrane-derived sul-
phidopeptide leukotrienes as well as the release of basic
proteins from the eosinophil crystalloid granule (23). Alter-
natively, or in addition, T cell activation may be associated
with the generation of histamine releasing factors, which in
turn activate basophils and/or mast cells to release hista-
mine with subsequent narrowing of already hyperrespon-
sive airways (24). Direct triggering of bronchoconstriction
by release of an unidentified T cell mediator may be another
possible mechanism. Studies currently underway involving
fiberoptic bronchoscopy with BAL and bronchial biopsy,
performed at time intervals after peptide-induced LAR, will
enable us to test these hypotheses. Our findings are thus of
clinical significance, because they may help to identify the
Figure 5. Presentation of FC1P 2 and 3 on more than one HLA-DR molecule. (A) Proliferation of a cat allergen extract–specific T cell line from sub-
ject R03 (DRB1*1301) cultured with fibroblast cell lines transfected with either DRB1*1301 or DRB1*1302 in the presence of medium alone and pep-
tides FC1P 1, 2, and 3. FC1P 3 is presented by DRB1*1301 and DRB1*1302. The amino acid sequences of DRB1*1301 and DRB1*1302 (a) show the
single amino acid difference at position 86 between the two molecules. (B) Proliferation of T cells from subject R06 (DRB1*0408) cultured with a fibro-
blast cell line transfected with DRB1*0405 in the presence of medium alone and peptides FC1P 1, 2, and 3. FC1P 2 is presented to DRB1*0408 T cells
by DRB1*0405. The amino acid sequences of DRB1*0405 and DRB1*0408 (b) show the single amino acid difference in the peptide binding regions at
position 57 of the two alleles. *Sequence not available. Dashes indicate homology with DRB1*0101.
Figure 6. Repeat challenge with a second injection of FC1P demonstrates transient attenuation of the LAR. (A) Rechallenge with peptides after 2–6 wk.
Three subjects were rechallenged with the same dose of FC1P as the first challenge (,); no LAR was observed after intradermal injection of FC1P (.).
(B) Rechallenge with peptides after 12 mo. Three subjects were rechallenged with FC1P (80 mg) more than 12 mo after the initial challenge. LARs of
similar magnitude were observed after the first (,) and the second (.) challenge. Control day, s.1892 T Cell Peptide Epitope–induced Late Asthmatic Reactions
critical mediator(s) involved in T cell– as opposed to mast
cell–dependent airway narrowing. This may have particular
relevance to ongoing chronic asthma, which is believed to
have an important T cell component (15, 16) but where the
sequence of events between T cell activation and bronchial
obstruction are incompletely understood.
It is intriguing that intradermal injection of peptides pro-
duced no visible local reaction in the nine subjects but
caused marked changes in the airways. One explanation for
a reaction at a distal site is that peptides are presented by
skin Langerhans cells to circulating T lymphocytes that bear
putative T cell homing receptors (analogous to the cutane-
ous lymphocyte-associated antigen described in patients
with atopic dermatitis; reference 25) and that these then
traffic to the airways. Alternatively, the peptide may be ab-
sorbed via the circulation or lymphatics and reach the air-
ways, where they are taken up by bronchial APCs that in
turn interact with locally sensitized T cells.
Related to the mechanism of T cell peptide epitope–
induced asthma is the variation in responsiveness amongst
the subjects studied, with only 9/40 responding with an
isolated LAR. There was no association between the ability
of a particular peptide to elicit a T cell–dependent prolifer-
ative response in vitro and its capacity to evoke LAR after
intradermal injection in vivo, i.e., in vitro mitogenic re-
sponses were observed in the absence of an elicited in vivo
effect (Fig. 2). These findings cannot be explained solely by
the lack of the appropriate HLA haplotype in the nonre-
sponders, as many of these also expressed DR1, DR4, or
DR13 (Table I). We believe that responsiveness or nonre-
sponsiveness was likely to have been a reflection of the dose
of peptide administered, with the threshold for developing
an LAR varying amongst individuals. It is clear that T cell re-
activity is likely to have been dependent on HLA molecules
restricting peptide presentation and T cell activation (26) to
FC1P, with subsequent induction of isolated LARs in sub-
jects in which a threshold dose was achieved. Of interest in
this regard was the apparent clustering of HLA-DR13
amongst the subjects in whom these LPRs were observed.
Haplotyping of reactors indicated that 4/9 reactors (44%)
possessed a DR13 allele, compared with only one 1/30 (3%)
nonreactors. Using transfected fibroblast cell lines, the abil-
ity of a variety of HLA-DR molecules to present FC1Ps to
allergen-specific T cell lines raised from subjects who de-
veloped LARs has been assessed. Initially, based upon the
high frequency of DR13 among those who developed
LARs, we examined the ability of DRB1*1301 and 1302
to present one or more of the FC1Ps to cat allergen extract–
specific T cell lines. We demonstrated that FC1P3 could be
presented by both DRB1*1301 and 1302. These micro-
variants of DR13 differ by only one residue at position 86
(valine®glycine; Fig. 6 A), and our results suggest, there-
fore, that this residue is not critical for the binding of this
peptide. Furthermore, we have demonstrated the ability
of DRB1*1302 to present FC1P3 to T cells from a
DRB1*1301 donor, indicating a degree of degeneracy in T
cell recognition of this peptide in the context of closely re-
lated microvariants of DR13. The ability of DRB1*1303,
which differs from 1301 and 1302 more substantially, to
present peptide FC1P3 is currently under investigation.
Investigation of the ability of DRB1*0101 to present
FC1Ps revealed promiscuous binding of FC1P3 to both
DR1 and DR13 molecules. As shown in Fig. 5 a, the se-
quences of DRB1*0101 and DRB1*1301/1302 differ sub-
stantially within the peptide binding region of the mole-
cules. However, a precedent for promiscuous binding of a
single peptide (influenza HA 307–319) to both DR1 and
DR13 alleles has been described by Hickling et al. (27).
Three of the nine individuals who developed peptide-
induced LAR were DR41, although each expressed a dif-
ferent microvariant of DR4 (Table I). The ability of DR4
microvariants to present FC1Ps was investigated, and it was
established that DRB1*0405 was able to present FC1P2 to
cat allergen extract–specific T cells from both DRB1*0405
(autologous) and DRB1*0408 individuals. Thus, in com-
mon with FC1P3, the second FC1P appears to be capable
of binding to more than one HLA molecule. The ability of
this peptide to bind to other DR4 microvariants is cur-
rently under investigation.
Our findings suggest that induction of the LAR results
from MHC-restricted T cell activation. The limited clinical
benefit that has so far been observed with peptide immu-
notherapy may therefore be explained by the fact that only
a proportion of patients treated will have been capable of
reacting to the peptides, as MHC restriction has not been
accounted for (19–21). Furthermore, the observation that
individual allergen peptides are capable of promiscuous
HLA binding may hold promise for the development of
MHC-restricted peptide-based therapies. All of the subjects
developing asthmatic reactions expressed DR1, 4, or 13.
However, a significant proportion of individuals who did
not react also expressed these HLA types. The fact that
these subjects did not progress to develop LARs may be
due to a deficit in the subjects’ T cell repertoire. Alterna-
tively, the lowest possible dose that was found to induce an
LAR was used in all individuals, and some of the volun-
teers who did not respond may have required a higher dose
of FC1P to trigger an asthmatic reaction.
It should be noted that the amount of peptide required
for systemic administration was z10,000 times that of the
intact protein. However, there is clearly a dilutional effect
in a situation where an intradermal injection elicits a reac-
tion at a distal site. The minimum dose required to produce
an LAR will be calculated more accurately in studies in-
volving direct application of peptides into the airways. It
should also be appreciated that any bronchial reaction elic-
ited by intradermal injection of whole cat extract (which
can very occasionally occur but did not in this study)
would be predominantly anaphylactic in type, with an IgE/
mast cell–dependent bronchospasm occurring within 30 min
and usually sooner (28).
Recent studies have demonstrated that an initial transient
activation of T cells precedes the development of hypore-
sponsiveness (17). In support of this concept was the obser-
vation that in three of the patients studied, there was abro-
gation of the LAR on repeat administration of the same1893 Haselden et al.
dose of peptide that previously caused a 20% or greater fall
in FEV1 (Fig. 6 A). This is similar to the experience of
Norman et al. (19), who also observed that there was a
progressive decline in the incidence and severity of unto-
ward symptoms after continued treatment of cat allergy
with IPC1/IPC2, suggesting but not proving that some
form of tolerance may have developed after repeated ad-
ministration. In addition, three subjects who developed
LARs in response to FC1P were readministered the same
dose at an interval of greater than one year. All three devel-
oped LARs of approximately the same magnitude as those
that accompanied the initial challenge (Fig. 6 B). These ob-
servations suggest that the induction of hyporesponsiveness
after a single dose of FC1P is transient, lasting somewhere
between a few weeks and one year. Further studies are cur-
rently underway to define the precise duration of peptide-
induced hyporesponsiveness in humans. This may have fur-
ther clinical significance if repeated administration of MHC
class II–restricted T cell peptide epitopes produce safe and
effective long-term “tolerance.”
In conclusion, we have demonstrated that intradermal
injection of a linear peptide sequence within an allergen at a
high dose can elicit a late-phase response by a presumed T
cell–dependent mechanism in the absence of an IgE-medi-
ated reaction. This appears to be the first demonstration of
asthma provoked by MHC-restricted T cell activation.
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